Abstract
Background/Objectives: Tandem high-dose chemotherapy with autologous stem cell transplantation (ASCT) is used to intensify consolidation for high-risk neuroblastoma. One randomized trial supports it, but the wider evidence has not been synthesized quantitatively. Methods: We searched PubMed, Embase, Web of Science and Cochrane CENTRAL on 2 October 2026 for randomized and non-randomized studies comparing tandem with single ASCT for event-free survival (EFS) or overall survival (OS). The randomized trial was the main evidence. Non-randomized studies were grouped by analysis type and pooled with the trial if eligible and not at critical risk of bias. Missing hazard ratios (HRs) were derived from survival proportions and log-rank p values. Risk of bias was assessed with RoB 2 and ROBINS-I, and certainty with GRADE. Results: Of 698 records screened, five studies were included (one randomized trial, four non-randomized studies; 657 patients), and four were pooled (631 patients). In the trial, tandem ASCT improved EFS (HR 0.67, 95% CI 0.49–0.92). Eligible non-randomized studies gave a similar estimate (HR 0.65, 0.43–0.99); the pooled HR was 0.66 (0.51–0.85; I2 = 0%), about 13 more patients per 100 event-free at 3 years. The pooled HR for OS was 0.82 (0.57–1.17; two studies). EFS estimates ranged from 0.62 to 0.68 in sensitivity analyses but were attenuated after adding a registry that included relapsed and adult patients (0.82, 0.56–1.19). Certainty was moderate for EFS and low for OS. Conclusions: Tandem ASCT probably improves EFS in high-risk neuroblastoma; its effect on OS is uncertain. Whether the benefit depends on anti-GD2 immunotherapy, or persists against busulfan/melphalan, remains untested.